IPO Databook: Apnimed (APMD US) - Jul 2026

• Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases. Its sole clinical product candidate, Oxnimbi, is an investigational fixed-dose neuromuscular modulator for.
• NDA for Oxnimbi was submitted to the FDA in April 2026 and accepted in July 2026. Oxnimbi met its primary endpoint in Phase 3 trials.
• As of March 31, 2026, cash and cash equivalents were $46,886, with an accumulated deficit of $329,625. There is substantial doubt about the ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.